Artios

Artios is a leading independent DNA Damage Response (DDR) company focussed on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programmes, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.

http://www.artiospharma.com/

Team Members
more about
Alicia Irurzun-Lafitte
more about
Hakan Goker
Latest News Entry
2016/11/02
Artios Pharma Ltd: Strengthened Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy

Strengthened Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy

Cambridge, UK, 2 November 2016. Artios Pharma Ltd., a newly launched private company focussed on developing novel cancer treatments targeting the DNA Damage Response (DDR), today announces it has strengthened its management team with the appointment of Dr Simon Boulton as Vice President (VP) Science Strategy.

all portfolio news